We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
PharmAthene has announced it has been awarded a multiyear contract valued at up to $213 million from the Department of Defense (DOD) U.S. Army Space and Missile Command for advanced development of the company's broad-spectrum chemical nerve agent prophylaxis, Protexia.
A year after its last review, the European Medicines Agency (EMEA) has announced it will look again at the cardiovascular safety of non-selective non-steroidal anti-inflammatory drugs (NSAIDs).
The
international humanitarian organization Médecins Sans Frontières (MSF) has issued a statement warning that a patent challenge filed by Novartis set to be heard in the Chennai High Court in India today may have serious implications for future access to essential drugs.
The World Health Organization Western Pacific Region has said it is working closely with international partner agencies for AIDS prevention and treatment.
Takeda Pharmaceutical Co. plans to increase its spending on research to speed up the development of new drugs, with the patents on many of its existing products to end over the next few years, its president told the Yomiuri Shimbun.
The worst forms of the killer tuberculosis bug have been gaining ground in the United States, alarming public health officials over imported drug-resistant strains of a disease that is mostly under control in this country.
Belgium's UCB on Monday said it agreed to pay $5.6 billion for Germany's Schwarz Pharma, the third multibillion-dollar takeover in the European pharmaceutical industry in the past five days.